Fostamatinib Seems Effective for Immune Thrombocytopenia

Overall response of platelet count ≥ 50,000/ μ L seen in 43 percent of patients
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pathology, Pharmacy, Journal, Source Type: news

Related Links:

Authors: Kounis NG, Koniari I, Soufras GD, Tsigkas G, Plotas P, Davlouros P, Hahalis G PMID: 32214073 [PubMed - as supplied by publisher]
Source: International Angiology - Category: Cardiology Tags: Int Angiol Source Type: research
Immune checkpoint inhibitors (ICIs) have been extensively investigated as a novel form of cancer therapy against a range of malignancies including urothelial carcinoma [1]. Notably however, they have also been associated with unique toxicities known as immune-related adverse events (irAEs) which may involve any organs, including haematologic systems [2]. The precise mechanisms involved in different irAEs are largely unknown, but they are believed to be associated with aberrant activation of immune systems induced by ICIs.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Letter to the Editor Source Type: research
Condition:   Low/Intermediate Risk-1 MDS Interventions:   Drug: Danazol + rhTPO (recombinant human thrombopoietin injection);   Drug: Danazol + sodium chloride Sponsor:   Peking Union Medical College Hospital Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract BACKGROUND: A standard approach to the recognition and management of major bleeding in immune thrombocytopenia (ITP) is lacking. METHODS: Retrospective cohort study of ITP patients presenting to the ED with severe thrombocytopenia (platelet count
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research
This article summarizes the FDA review and the data supporting the approval of ado-trastuzumab emtansine as a component of treatment for patients with HER2-positive EBC with residual disease. PMID: 32217612 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
AbstractThrombotic Microangiopathy (TMA) is a heterogeneous collection of syndromes that encompasses TTP, HUS, and other processes characterized by thrombocytopenia, microangiopathic hemolytic anemia, and, if untreated, organ failure and death. Novel therapies have recently been approved for the management of certain thrombotic microangiopathies, including caplacizumab for immune-mediated TTP, and eculizumab for atypical HUS. These options have complicated the standard workflow, which includes initiation of plasma exchange until ADAMTS13 testing can be resulted. Given such results may take several days, there is indecision...
Source: Journal of Thrombosis and Thrombolysis - Category: Hematology Source Type: research
We describe a 25-year-old man with isolated thrombocytopenia initially. He experienced recurrent seizures with stable thrombocytopenia after the first seizures related to intracranial hemorrhage. He was identified a novel c.3452C>T mutation by targeted exome sequencing. If a patient with thrombocytopenia shows recurrent seizures as well as renal, hearing, visual symptoms, MHA should be suspected and the targeted exome sequencing is considered an effective diagnostic tool.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
The success of Intravenous Immunoglobulin in treating autoimmune and inflammatory processes such as immune thrombocytopenia purpura and Kawasaki disease has led to renewed interest in developing recombinant molecules capable of recapitulating these therapeutic effects. The anti-inflammatory properties of IVIG are, in part, due to the Fc region of the IgG molecule, which interacts with activating or inhibitory Fcγ receptors (FcγRs), the neonatal Fc Receptor, non-canonical FcRs expressed by immune cells and complement proteins. In most cases, Fc interactions with these cognate receptors are dependent upon avidity...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusion: Apatinib is actively used in treating patients with recurrent AM. A randomized trial and phase II clinical trial of this inhibitor should be performed to further evaluate its efficacy in treating malignant meningioma. PMID: 32212907 [PubMed - as supplied by publisher]
Source: Cancer Biology and Therapy - Category: Cancer & Oncology Authors: Tags: Cancer Biol Ther Source Type: research
Authors: Davenport P, Liu ZJ, Sola-Visner M Abstract A growing body of research has made it increasingly clear that there are substantial biological differences between fetal/neonatal and adult megakaryopoiesis. Over the last decade, studies revealed a developmentally unique uncoupling of proliferation, polyploidization, and cytoplasmic maturation in neonatal MKs that results in the production of large numbers of small, low ploidy, but mature MKs during this period of development, and identified substantial molecular differences between fetal/neonatal and adult MKs. This review will summarize our current knowledge ...
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research
More News: Cancer & Oncology | Pathology | Thrombocytopenia